EOLS Logo

Evolus, Inc. (EOLS) 

NASDAQ
Market Cap
$802.6M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
528 of 775
Rank in Industry
31 of 47

Largest Insider Buys in Sector

EOLS Stock Price History Chart

EOLS Stock Performance

About Evolus, Inc.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Insider Activity of Evolus, Inc.

Over the last 12 months, insiders at Evolus, Inc. have bought $0 and sold $10.03M worth of Evolus, Inc. stock.

On average, over the past 5 years, insiders at Evolus, Inc. have bought $3.4M and sold $18.4M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 174,967 shares for transaction amount of $1.3M was made by Malik Vikram (director) on 2023‑08‑15.

List of Insider Buy and Sell Transactions, Evolus, Inc.

2024-09-06SaleChief Financial Officer
3,276
0.0053%
$14.98$49,074+12.10%
2024-08-30SaleChief Marketing Officer
5,631
0.0089%
$15.85$89,251+3.46%
2024-06-06SaleSee Remarks
175,940
0.2852%
$12.59$2.21M+22.06%
2024-06-05SaleSee Remarks
155,278
0.2465%
$12.92$2.01M+15.90%
2024-06-04SaleSee Remarks
140,214
0.2217%
$12.73$1.78M+16.91%
2024-06-03Saledirector
7,500
0.0119%
$12.96$97,203+14.97%
2024-05-14Saledirector
6,718
0.0106%
$12.60$84,654+7.78%
2024-05-13Saledirector
28,000
0.0459%
$12.93$362,012+8.72%
2024-05-13Saledirector
3,643
0.0059%
$12.72$46,356+8.72%
2024-05-10SaleSee Remarks
16,051
0.0256%
$12.72$204,127+7.41%
2024-05-10SaleSee Remarks
3,441
0.0055%
$12.72$43,761+7.41%
2024-05-10SaleChief Financial Officer
2,423
0.0039%
$12.72$30,814+7.41%
2024-03-27SaleSee Remarks
6,236
0.01%
$13.86$86,431-5.29%
2024-03-19SaleSee Remarks
96,566
0.1564%
$13.92$1.34M-4.93%
2024-03-19SaleSee Remarks
27,603
0.0447%
$13.92$384,350-4.93%
2024-03-19SaleChief Financial Officer
5,672
0.0092%
$13.92$78,978-4.93%
2024-02-22SaleSee Remarks
7,706
0.0134%
$13.08$100,804+3.95%
2024-02-22SaleSee Remarks
1,821
0.0032%
$13.08$23,821+3.95%
2024-02-22SaleChief Financial Officer
1,821
0.0032%
$13.08$23,821+3.95%
2024-01-30Saledirector
11,931
0.0211%
$13.14$156,733+4.66%

Insider Historical Profitability

<0.0001%
Malik Vikramdirector
246514
0.3893%
$12.6847<0.0001%
GILL DAVID Ndirector
33964
0.0536%
$12.6823+8.2%
Medytox Inc.
3381326
5.3399%
$12.68159<0.0001%
Jafar Michael M.See Remarks
174851
0.2761%
$12.6811<0.0001%
BLANK SIMONE
54881
0.0867%
$12.6830<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$80.55M9.195.75M+45.17%+$25.07M0.05
Tang Capital Management, LLC$58.06M6.624.15M+33.9%+$14.7M0.22
BlackRock$45.65M5.213.26M-2.35%-$1.1M<0.01
Morgan Stanley$42.6M4.863.04M+17.81%+$6.44M<0.01
Nantahala Capital Management Llc$40.75M4.652.91M0%+$01.9
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.